Press releases

All press releases Regulatory

Regulatory press release 2025-08-26

First day of trading in subscription rights and BTAs moved to August 27

Regulatory press release 2025-08-25

Xspray publishes disclosure document regarding rights issue

Regulatory press release 2025-08-25

Xspray receives additional subscription undertakings of SEK 20 million in the ongoing rights issue

Press release 2025-08-19

Xspray Pharma Submits XS003 to the FDA – The Company’s Second Product Candidate from the HyNap Platform

Regulatory press release 2025-08-15

Interim Report Second Quarter 2025

Regulatory press release 2025-08-15

Xspray resolves on a rights issue of approximately SEK 130 million with an over-allotment issue and carries out debt refinancing

Regulatory press release 2025-08-12

Xspray Pharma signs license agreement with Handa Therapeutics – to receive up to double-digit royalty on Handa’s net proceeds

Regulatory press release 2025-07-11

XSpray Pharma achieves significant milestone – demonstrating bioequivalence with absorption advantages compared to Tasigna

Regulatory press release 2025-06-27

Xspray Pharma Passes FDA Pre-Approval Inspection – Key Regulatory Milestone Achieved for Dasynoc

Regulatory press release 2025-05-14

FDA sets PDUFA-date for Xspray Pharma’s re-submitted application for Dasynoc®

IR contact

Jacob Nyberg, IRO

+46 (0)70 767 08 83

info@xspray.com

Subscribe